


## AMENDMENTS TO AND LISTING OF CLAIMS


1. (Currently amended) A compound of formula I




wherein

R<sub>1</sub> is C<sub>1-6</sub>-alkyl optionally substituted by OH, C<sub>1-2</sub>-alkoxy or 1-to-6 fluorine atoms; C<sub>2-6</sub>-alkenyl; or C<sub>2-6</sub>-alkynyl;


R<sub>2</sub> is a radical of formula a[[,]] or b or c



a



b



c

wherein

R<sub>6</sub> is C<sub>1-12</sub>-alkyl optionally substituted by halogen, by an optionally-substituted cycloalkyl, by an optionally-substituted phenyl, by an optionally-substituted heteroaryl, or by an optionally-substituted heterocyclic residue, wherein the C<sub>1-12</sub>-alkyl optionally is interrupted by one or more O or C=O; and wherein the phenyl, heteroaryl, cycloalkyl, and/or heterocyclic residue may be substituted by 1-to-5 substituents independently selected from hydroxy; halogen; C<sub>1-4</sub>-alkyl; C<sub>1-4</sub>-alkyl substituted by 1-to-5 fluorine atoms; C<sub>1-4</sub>-alkoxy; C<sub>1-4</sub>-alkoxy substituted by 1-to-5 fluorine atoms; cyano; phenyl; and phenyl substituted by 1-to-5 substituents independently selected from hydroxy, halogen, C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkoxy, and cyano;

R<sub>7</sub> is H, optionally-substituted phenyl, optionally-substituted heteroaryl, wherein the phenyl and/or heteroaryl, independently, may be substituted by 1-to-5 substituents independently selected from

hydroxy; halogen; C<sub>1-4</sub>-alkyl; C<sub>1-4</sub>-alkyl substituted by 1-to-5 fluorine atoms; C<sub>1-4</sub>-alkoxy; C<sub>1-4</sub>-alkoxy substituted by 1-to-5 fluorine atoms; and cyano;

X is O, ~~C=O, S or a bond~~;

Z is N or O;

R<sub>3</sub> is -A-B-COOH, wherein each of A and B, independently, is a bond, C=O or CDE, wherein each of D and E, independently, is H, halogen, C<sub>1-3</sub>-alkyl[,] or OH; with the proviso that A and B are not both C=O; and


each of R<sub>4</sub> and R<sub>5</sub>, independently, is H, C<sub>1-4</sub>-alkyl optionally substituted by 1, 2 or 3 halogen atoms, or acyl, wherein acyl is a residue W-CO, wherein W is C<sub>1-6</sub>-alkyl, C<sub>3-6</sub>-cycloalkyl, phenyl or phenylC<sub>1-4</sub>-alkyl;

with the proviso that when R<sub>4</sub> is H, R<sub>5</sub> is H, R<sub>3</sub> is COOH, R<sub>2</sub> is a radical of formula a and R<sub>7</sub> is H, and either i) ~~either~~ R<sub>1</sub> is CH<sub>2</sub>OH and XR<sub>6</sub> is ~~a radical an unsubstituted~~ C<sub>1-12</sub>-alkyl ~~not substituted, then XR<sub>6</sub> that~~ is not para to (CH<sub>2</sub>)<sub>2</sub>-CR<sub>1</sub>R<sub>3</sub>(NR<sub>4</sub>R<sub>5</sub>); or

ii) ~~or~~ R<sub>1</sub> is CH<sub>3</sub> and XR<sub>6</sub> is ~~a radical an unsubstituted~~ OC<sub>1-12</sub>-alkyl ~~not substituted, then XR<sub>6</sub> that~~ is not meta to (CH<sub>2</sub>)<sub>2</sub>-CR<sub>1</sub>R<sub>3</sub>(NR<sub>4</sub>R<sub>5</sub>);

where heteroaryl is pyridyl, pyrimidinyl, pyrazinyl, furyl, oxazolyl, isoxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl or pyrazolyl; cycloalkyl is C<sub>3-6</sub>-cycloalkyl; and a heterocyclic residue is tetrahydrofuryl, tetrahydropyranyl, aziridinyl, piperidinyl, pyrrolidinyl or piperazinyl;  
in free form or in salt form.

2. (Currently amended) A compound of formula II



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>5</sub> are as defined in Claim 1, and R'<sub>4</sub> is a protecting group selected from benzyl, p-methoxybenzyl, methoxymethyl, tetrahydropyranyl, trialkylsilyl, acyl where acyl is a residue W-CO wherein W is C<sub>1-6</sub>-alkyl, C<sub>3-6</sub>-

cycloalkyl, phenyl or phenylC<sub>1-4</sub>-alkyl, tert-butoxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl and trifluoroacetyl, or a salt thereof.

3. (Currently amended) A compound according to Claim 1 which is selected from (R)-3-amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.

4. (Currently amended) A pharmaceutical composition ~~containing~~ comprising a compound according to Claim 1 in free form or in a pharmaceutically-acceptable salt form, together with one or more pharmaceutically-acceptable diluents or carriers therefor.


5, 6. (Canceled)

7. (Withdrawn by the Examiner) A pharmaceutical combination comprising a compound according to claim 1 in free form or in a pharmaceutically acceptable salt form and a further agent selected from immunosuppressive, immunomodulating, anti-inflammatory and chemotherapeutic agents.

8. (Canceled)

9. (Withdrawn by the Examiner) A method of treatment or prevention of allograft rejection, autoimmune disease, graft versus host disease, inflammatory diseases, myocarditis, hepatitis, ischemia/reperfusion injury, hemorrhage shock, traumatic shock, angiogenesis, Alzheimer's disease, cancer, infectious diseases or senile dementia, comprising administering to said subject a therapeutically effective amount of a compound according to claim 1 in free form or in a pharmaceutically acceptable salt form.

10. (Withdrawn by the Examiner) The method of claim 9 wherein the compound is of formula II




wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_5$  are as defined in claim 1, and  $R'_4$  is a protecting group, or a salt thereof.

11. (Withdrawn by the Examiner) The method of claim 9 wherein the compound is selected from (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.

12, 13. (Canceled)

14. (Withdrawn by the Examiner) A method of treatment or prevention of allograft rejection, autoimmune disease, graft versus host disease, inflammatory diseases, myocarditis, hepatitis, ischemia/reperfusion injury, hemorrhage shock, traumatic shock, angiogenesis, Alzheimer's disease, cancer, infectious diseases or senile dementia, comprising administering to said subject a therapeutically effective amount of a composition according to claim 4.


15. (Withdrawn by the Examiner) The composition of claim 14 wherein the compound is of formula II



wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_5$  are as defined are as defined in claim 1, and  $R'_4$  is a protection group, or a salt thereof.

16. (Withdrawn by the Examiner) The method of claim 14 wherein the compound is selected from (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.

17. (Withdrawn by the Examiner) The pharmaceutical combination of claim 7 wherein the compound is of formula II



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>5</sub> are as defined are as defined in claim 1, and R'<sub>4</sub> is a protecting group, or a salt thereof.

18. (Withdrawn by the Examiner) The pharmaceutical combination of claim 7 wherein the compound is selected from (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.